RT Journal Article
T1 Influence of the technique and comorbidities in hypofractionated radiotherapy for prostate cancer
A1 Correa Generoso, Raquel
A1 Navarro, Inmaculada
A1 Lobato, Mario
A1 Otero, Ana
A1 Jerez, Inmaculada
A1 Rico, José Manuel
A1 Zapata Martínez, Irene
A1 Lupiáñez Pérez, Yolanda
A1 Medina Carmona, José Antonio
A1 Olmos, David
A1 Gómez-Millán Barrachina, Jaime
K1 Próstata - Cáncer
AB To analyze the differences in toxicity and biochemical relapse-free survival with hypofractionated radiotherapy with three-dimensional radiotherapy (3D-CRT) or volumetric arc therapy (VMAT) for prostate cancer taking into account comorbidity measured using the Charlson Comorbidity Index (CCI).  Methods: From January 2011 to June 2016, 451 patients with prostate cancer were treated with 60 Gy (20 daily fractions). VMAT or 3D-CRT was used. Distribution by stage: 17% low-risk, 27.2% intermediate-risk; 39.2% high-risk, 16.6% very high-risk. Mean CCI was 3.4. Results: With a median follow up of 51 months, most patients did not experience any degree of acute GI toxicity (80.9%) compared to 19.1%, who experienced some degree, mainly G-I /II. In the multivariate analysis, only technique was associated with acute GI toxicity ≥ G2. Patients treated with VMAT had greater acute GI toxicity compared with those who received 3D-CRT (23.9% vs. 13.5%, p = 0.005). With respect to acute GU toxicity, 72.7% of patients experienced some degree, fundamentally G-I/II. Neither age, CCI, nor androgen deprivation therapy (ADT) were associated with greater toxicity. Overall survival at 2, 5 and 7 years was 97%, 88% and 83% respectively. The only factor with statistical significance was CCI, with a greater number of events in individuals with a CCI ≥ 4 (p < 0.03). Conclusions: Hypofractionated radiotherapy for prostate cancer is an effective, well-tolerated treatment even for elderly patients with no associated comorbidity. Longer follow up is needed in order to report data on late toxicity.
PB Springer Link
YR 2020
FD 2020
LK https://hdl.handle.net/10630/33926
UL https://hdl.handle.net/10630/33926
LA eng
NO Correa R, Navarro I, Lobato M, Otero A, Jerez I, Rico JM, Zapata I, Lupiañez Y, Medina JA, Olmos D, Gómez-Millán J. Influence of the technique and comorbidities in hypofractionated radiotherapy for prostate cancer. Clin Transl Oncol. 2020 Mar;22(3):311-318. doi: 10.1007/s12094-019-02224-6. Epub 2019 Nov 12. PMID: 31721011.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 19 ene 2026